The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/
DrugChatter: How does lyrica affect liver function? Read Post »
The “Smarter Monopoly” Debate Is Here—and It’s About Orphan Drugs
Big pharma has a reputation for monopolies. But the real fight in drug policy isn’t just about whether exclusivity exists—it’s about what kind of exclusivity we’re willing to pay for, an…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic Loss of Exclusivity
The market doesn’t wait for your pipeline.
When a biologic approaches loss of exclusivity, the clock starts ticking—not ju…
Pharma’s “patent squeeze” isn’t a myth—it’s a strategy.
For years, the public conversation around drug pricing has focused on one moment: when a blockbuster patent expires and generics rush in. But the real story is more tactical—and more continuous….
Patients aren’t asking “about patents.” They’re asking, “Will I be able to get my medicine?”
If you’ve spent any time reading what people search online, you’ll notice something telling: the questions rarely start with legal jargon. They start with life…
Drug Switching Questions: What Patients Are Really Asking Online Read Post »
Evergreen strategies are getting smarter—and so do the teams trying to beat them.
For years, “brand” companies have used a familiar playbook: extend exclusivity not by inventing a cure, but by tightening the legal perimeter around an existing one. New …
GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Actually Changes
The life sciences industry has a habit of treating “AI breakthroughs” like weather—interesting, inevitable, and mostly outside our control. But OpenAI’s la…
GPT-Rosalind and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes Read Post »
Patent cliffs don’t just hit revenue—they reshape the entire payer conversation.
If you’re waiting until a drug’s exclusivity is already expiring to think about “what happens next,” you’re already late. The next phase of competition is rarely decided…
Beat the Patent Cliff: How to Trigger Payer Strategy Campaigns Before Drug Patent LOE Read Post »
ð¨ AI just hit the drug patent wall—and it didn’t slow down.
OpenAI’s GPT-4o (and the broader push toward AI-assisted scientific reasoning) is moving from “cool demos” to something far more consequential: speeding up how companies find, interpret, an…
OpenAI’s GPT-Rosalind = Smashed Drug Patent Cliffs and 70% Faster ANDAs Read Post »
Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive as a thunderclap. They arrive as a filing.
A Paragraph IV challenge can look like a legal event on pape…
Get new actionable insights and updates from BiotechBlog
